This article is more than 5 years old. Information may no longer be current.

VIDEO: HemOnc Today Chief Medical Editors discuss key takeaways from ASCO Annual Meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, and John Sweetenham, MD, FRCP, FACP, Chief Medical Editors of HemOnc Today, discuss key studies and themes from the ASCO Annual Meeting.

Sweetenham offered perspective on the long-term follow-up of a study designed to evaluate rituximab (Rituxan; Genentech, Biogen) in patients with lymphoma, in which the drug failed to improve survival compared with standard of care.

In addition, he reviewed the study designed to evaluate larotrectinib (LOXO-101, Loxo Oncology) — the first selective small-molecule pan-tropomyosin receptor kinase inhibitor — which demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions.

Raghavan discussed two studies designed to evaluate the impact of abiraterone (Zytiga, Janssen Oncology) on survival in advanced prostate cancer.

“This year, there have been a series of papers that question if you abiraterone prednisone to androgen suppression, does that improve outcome?” Raghavan said. – by Kristie L. Kahl

Disclosure: Raghavan and Sweetenham report no relevant financial disclosures.